TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01950871

Intervention type: DEVICE
Group type: OTHER
Intervention: Prostate HistoScanning
Description: In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
Study: NCT03010124

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Blood sample
Study: NCT04640337

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPE applied, participants believe they are receiving IPE
Description: Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Participants will believe they are receiving IPE.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IPE applied, participants believe they are receiving placebo
Description: Participants will receive a total of 3 sessions of IPE, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. IPE will be applied following the standard protocol for PT. Subjects will be led to belie

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IPE not applied, participants believe they are receiving IPE
Description: Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin but the current will not be passing th

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IPE not applied, participants believe they are receiving placebo
Description: Participants will receive a total of 3 sessions of IPE-placebo, with a time interval of one week between the 1st and 2nd session and 2 weeks between the 2nd and 3rd session. The needle will be inserted under the skin, subjects will be led to believe that the intensity of the current is below the threshold necessary to cause changes in the tissue.
Study: NCT00766038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human Growth Hormone
Description: 400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SC injection daily
Study: NCT00982865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MSC1936369B
Study: NCT02348775

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GlyNAC (combination of glycine and n-acetylcysteine)
Description: HIV patients will be studied before and after receiving GlyNAC
Study: NCT01973712

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Locked Compression Plating

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retrograde Intramedullary Nailing (RIMN)
Study: NCT02216864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple Subcision
Description: At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
Study: NCT01497639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interleaving stimulation mode (Medtronic)
Description: Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interleaving stimulation mode (Medtronic)
Description: Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double monopolar stimulation mode (Medtronic)
Description: Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Double monopolar stimulation mode (Medtronic)
Description: Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
Study: NCT02145286

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
Study: NCT04305522

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 1
Description: Probiotic mixture with maltodextrin as a carrier.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator with maltodextrin as a carrier.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic 2
Description: Probiotic mixture with maltodextrin as a carrier.
Study: NCT02458755

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg
Description: Atorvastatin 40mg or Rosuvastatin 20mg
Study: NCT03380260

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paranoia Induction
Description: Behavioral procedure involving social exclusion and negative feedback to induce paranoia
Study: NCT01199029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: 10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: 10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04308515
Description: Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Study: NCT02761304

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Study: NCT01973777

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IUB
Description: intrauterine contraceptive device
Study: NCT00689468

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial osteopathic manipulative treatment.
Description: A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cranial osteopathic manipulative treatment.
Description: A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea
Description: 1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea
Description: 1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham osteopathic manipulative treatment
Description: Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sham osteopathic manipulative treatment
Description: Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Echinacea purpurea placebo
Description: An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Echinacea purpurea placebo
Description: An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
Study: NCT01183143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GONAL-f®
Description: GONAL-f® will be administered subcutaneously to subjects between Day 2 and Day 5 of their cycle with a starting dose of 75 International Units (IU) per day for subjects who undergo ovulation induction (OI)/artificial insemination (IUI) and between 150 and 225 IU per day for subjects who undergo in-vitro fertilization (IVF). For subjects who undergo OI/IUI, the dose will be increased by 37.5 IU after Day 14 up to Week 4 if no ovarian response is observed.
Study: NCT00307151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 4 mg/kg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 4 mg/kg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 4 mg/kg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: 4 mg/kg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: 16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: 16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m\^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m\^2/dose to max 200 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m\^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m\^2/dose to max 200 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: 180 mg/m\^2 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: 180 mg/m\^2 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: 180 mg/m\^2 twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine
Description: 180 mg/m\^2 twice daily
Study: NCT01469338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide pamoate
Description: Given IM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide acetate
Description: Given SC
Study: NCT02756728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-505
Description: Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dose melphalan
Description: High dose melphalan (HDM)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High dose melphalan
Description: High dose melphalan (HDM)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Description: Autologous stem cell transplantation (ASCT)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Autologous stem cell transplantation
Description: Autologous stem cell transplantation (ASCT)
Study: NCT01653288

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Coach
Description: Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Coach
Description: Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
Study: NCT00950508

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High volume plasma exchange
Description: 3 high volume plasma exchanges over 3 days

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard medical treatment
Description: Standard medical treatment
Study: NCT04350853

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical extrusion
Description: Surgically coronal reposition of the tooth
Study: NCT01221064

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early drainage removal
Description: Drainage will be removed in postoperative day 1

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Late drainage removal
Description: Drains will be kept until daily drainage is 30ml and then removed
Study: NCT00897663

Intervention type: GENETIC
Intervention: gene expression analysis

Intervention type: GENETIC
Intervention: microarray analysis

Intervention type: GENETIC
Intervention: protein expression analysis

Intervention type: OTHER
Intervention: diagnostic laboratory biomarker analysis

Intervention type: OTHER
Intervention: immunohistochemistry staining method
Study: NCT01388673

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy
Description: The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
Study: NCT04395339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialotetrahexosyl ganglioside (GM1)
Description: Ganglioside-Monosialic Acid is added into 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 250 mL of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 15 days. The first dose is given at 1 day before the start of the radiotherapy.
Study: NCT02982954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified Dose on Specified Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified Dose on Specified Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified Dose on Specified Day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified Dose on Specified Day
Study: NCT03435848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BST-236
Description: 1 to 4 courses
Study: NCT02807480

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based therapy
Description: Exposure-based therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation therapy
Description: Behavioral Activation therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based behavioral assessment
Description: Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based behavioral assessment
Description: Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys and Interviews
Description: Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys and Interviews
Description: Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography (EEG)
Description: Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
Study: NCT04467424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine, propofol
Description: anesthesia with ketofol in pediatric surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine, propofol, lidocaine
Description: anesthesia with ketofol plus lidocaine in pediatric surgery